An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes
A Pilot Study to Evaluate the Safety and Feasibility of Autologous Tolerogenic Dendritic Cells Loaded With Proinsulin Peptide (C19-A3) in Patients With Type 1 Diabetes
Sponsor: City of Hope Medical Center
Listed as NCT04590872, this observational or N/A phase trial focuses on Type 1 Diabetes Mellitus and remains ongoing. Sponsored by City of Hope Medical Center, it has been updated 17 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Apr 23, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Feb 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
▶ Show 12 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
This phase I trial investigates the side effects of PIpepTolDC vaccine in treating patients with type 1 diabetes who use insulin and don't have any other diabetes-related health complications. Type 1 diabetes is an autoimmune disease. This means that the immune system, which usually protects against foreign invaders like bacteria and viruses, attacks the body's insulin-producing betacells in the pancreas (autoimmune response). Overtime, the beta cells are destroyed by the immune system. To stay alive, people with type 1 diabetes must use insulin. PIpepTolDC vaccine is a type of immunotherapy (a treatment that uses a person's own immune system) that works like an allergy shot. The vaccine is made using one's own immune cells (dendritic cells) and a beta cell protein. The vaccine may teach the immune system to stop attacking the beta cells, which may help the beta cells recover and make enough insulin to control blood sugar levels. The vaccine may also help reduce future type 1 diabetes related complications.
Contact Information
- City of Hope Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .